Analysis and Reflection on the Current Situation of International Public Reporting of Adverse Drug Reactions

Abstract

Abstract: A relatively perfect adverse drug reactions monitoring system has been established in China. The public was encouraged to report adverse drug reactions in our country while the number of the public reports was very small over the years. To provide reference for the establishment of public reporting model of adverse drug reactions in China, current situations of the public reporting of adverse drug reactions in the developed countries mainly including the United States, Canada, Australia and the UK was analyzed, and the laws and regulations, the reporting ways and the reporting forms were summarized.

Key words: international, adverse drug reactions monitoring, spontaneous reporting, public reporting

CLC Number:

R994.11

CHANG Hong, TIAN Yue-jie, LIU Hong-liang, WU Shi-fu, WANG Ling, LI Yu-ji, WANG Xiao-jun, WANG Bing-jie, ZHAO Ru-min, ZHAO Hui-rong, ZHANG Yun-duan. Analysis and Reflection on the Current Situation of International Public Reporting of Adverse Drug Reactions[J]. Chinese Journal of Pharmacovigilance, 2017, 14(7): 419-423.

References

[1] Basch E. The Missing Voice of Patients in Drug-Safety Reporting[J]. New England Journal of Medicine, 2010, 362(10):865-869.
[2] Margraff F, Bertram D. Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries[J]. Drug Safety, 2014, 37(6):409-419.
[3] 边蕾,赵频,杨悦.药物警戒中患者直接报告情况研究[J].中国药物警戒, 2013, 10(10):609-613.
[4] H?rmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems[J]. Drug safety, 2015, 38(4): 337-347.
[5] van Hunsel F, H rmark L, Pal S, et al. Experiences with adverse drug reaction reporting by patients: an 11-country survey [J]. Drug safety, 2012, 35(1): 45-60.
[6] Sten Olsson. New WHO handbook on direct patient reporting[J/OL]. UPPSALA REPORTS,2012,(57):11.
[7] FDA. Section 1137: Patient Participation in Medical Product Discussions[EB/OL]. (2017-04-12)[2017-05-31]. http://www.fda.gov/ForPatients/PatientEngagement/ucm483931.htm.
[8] Health Canada. Good Pharmacovigilance Practices (GVP) Guidelines (GUI-0102) [EB/OL].(2013-02-11)(2017-07-01). https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/pharmacovigilance-guidelines-0102.html#a42.
[9] Australian Government. Therapeutic Goods Act 1989(Includes amendments up to:Act No. 47, 2017)[EB/OL].(2017-06-20)[2017-07-01]. https://www.legislation.gov.au/Details/C2017C00182.[10] The United Kingdom. Medicines Act 1968[EB/OL]. (1968-10-
25)[2017-07-01].http://www.legislation.gov.uk/ukpga/1968/67/introduction.
[11] 宋洋, 杨悦. 欧盟药物警戒体系建立运行与实施进展[J]. 中国药物警戒, 2014, 11(7):401-406.
[12] 王晓燕, 杨悦. 欧盟新的药物警戒法规简介与启示[J]. 中国药物警戒, 2013, 10(7):396-399.
[13] 严瑾, 邵蓉. 中英不良反应监测报告内容对比及启示[J]. 广东药学院学报, 2015, 31(2):235-239.
[14] Golomb B A, McGraw J J, Evans M A, et al. Physician response to patient reports of adverse drug effects[J]. Drug Safety, 2007, 30(8): 669-675.
[15] van Hunsel F, van der Welle C, Passier A, et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands[J]. European journal of clinical pharmacology, 2010, 66(11): 1143-1150.
[16] van Grootheest K, de Jong-van den Berg L. Patients' role in reporting adverse drug reactions[J]. Expert opinion on drug safety, 2004, 3(4): 363-368.
[17] de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in The Netherlands three years of experience[J]. Drug Safety, 2008, 31(6): 515-524.
[18] 陆逸雁, 李虹影, 盛红彬, 等. 不同人群药品不良反应认知度调查[J]. 中国药物警戒, 2009, 6(3):147-151.